Sign Up to like & get
recommendations!
1
Published in 2022 at "JCI Insight"
DOI: 10.1172/jci.insight.158444
Abstract: New strategies that augment T cell responses are required to broaden the therapeutic arsenal against cancer. CD96, TIGIT, and CD226 are receptors that bind to a communal ligand, CD155, and transduce either inhibitory or activating…
read more here.
Keywords:
activity anti;
cd96;
cross linking;
cd96 antibodies ... See more keywords